

**Amendment to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-73 Canceled

Claim 74 (currently amended): [A device for the treatment of aneurismal tissue]

An aneurismal tissue treatment device comprising:

at least one reservoir; and

at least one therapeutic agent within said reservoir;

wherein said reservoir is adapted for implantation external to an aneurysm site and delivers at least one therapeutic agent to said aneurismal tissue by means of a pump and tubing for the treatment of said aneurismal tissue[.] ; and

wherein said at least one therapeutic agent is selected from the group consisting of matrix metalloproteinase (MMP) inhibitors, antibiotics such as doxycycline and tetracycline, cyclooxygenase-2 (COX-2) inhibitors, angiotensin-converting enzyme (ACE) inhibitors, glucocorticoids, beta blockers, nitric oxide synthase (NOS) inhibitors, antioxidants, non-steroidal anti-inflammatory drugs (NSAIDs) and cellular adhesion molecules (CAMs), and combinations thereof.

Claim 75 (previously presented): The device of claim 74, wherein said pump is a mechanical, electrical, or osmotic pump.

Claim 76 (currently amended): The device of claim 74, wherein a first end of said tubing is in communication with said pump and a second end of said tubing is adapted to be located within the blood vessel lumen within or adjacent to the aneurysm sac.

Claim 77 (new): An aneurismal tissue treatment system comprising:  
a stent graft adapted for placement within a vessel lumen adjacent an aneurismal site; and

at least one implantable therapeutic agent delivery reservoir adapted to be implanted external said aneurismal site and further adapted to deliver a carrier comprising at least one therapeutic agent to said aneurismal site.

Claim 78 (new): The aneurismal tissue treatment system according to claim 77 wherein said implantable therapeutic agent delivery reservoir is a pump.

Claim 79 (new): The aneurismal tissue treatment system according to claim 77 wherein said carrier is a therapeutic agent solvent.

Claim 80 (new): The aneurismal tissue treatment system according to claim 78 wherein said pump is mechanical, electrical, or osmotic.

Claim 81 (new): The aneurismal tissue treatment system according to claim 77 further comprising a means for refilling said implantable therapeutic agent delivery reservoir with said therapeutic agent.

Claim 82 (new): The aneurismal tissue treatment system according to claim 77 wherein said at least one therapeutic agent is selected from the group consisting of matrix metalloproteinase (MMP) inhibitors, antibiotics such as doxycycline and tetracycline, cyclooxygenase-2 (COX-2) inhibitors, angiotensin-converting enzyme (ACE) inhibitors, glucocorticoids, beta blockers, nitric oxide synthase (NOS) inhibitors, antioxidants, non-steroidal anti-inflammatory drugs (NSAIDs) and cellular adhesion molecules (CAMs), and combinations thereof.

Claim 83 (new): The aneurismal tissue treatment system according to claim 77 wherein said at least one implantable therapeutic agent delivery reservoir delivers said at least one therapeutic agent to said aneurismal tissue by means of a pump and tubing for the treatment of said aneurismal tissue.